Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRT after early breast cancer
ACTRN12607000038493Phase 3Completed
- Sponsor
- Regional Oncologic Centre
- Start
- Mar 1997
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of estradiol valerate + dydrogesterone, DehydraTECH-estrogen and hydroxyprogesterone caproate in menopause and breast cancer (2 arms), sponsored by Regional Oncologic Centre. Primary endpoint: Breast cancer recurrence safety. Started Mar 1997; status: completed.
02
Drugs
estradiol valerate + dydrogesteroneDehydraTECH-estrogenhydroxyprogesterone caproate
03
Conditions
menopausebreast cancer
Beyond the preview
Go deeper on ACTRN12607000038493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12607000038493.